Pharmacogenetic testing of CYP metabolism may be conducted in individuals with suspected vitamin D-mediated hypercalcemia alongside careful differential diagnostics, including the 25(OH)D3:24,25(OH)2D3 ratio. The gene discussed is PPIG; the disease is Hypercalcemia.